Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: When to change? a perspective in 2009

Current Opinion in Hematology

Volumn 16, Issue 2, 2009, Pages 135-139

  Mauro, Michael J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chronic myelogenous leukemia; Kinase inhibitors; Management

Indexed keywords

CYTARABINE; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; HUMAN; MEDICAL DECISION MAKING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT RESPONSE;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 62249107926     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283257b2b     Document Type: Review

References (16)

1. Hochhaus A, Drucker BJ, Larson RA, et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract #25]. Blood 2007; 110.
2. Aoki E, Kantarjian H, O'Brien S, et al. High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia [abstract #6365]. J Clin Oncol 2006; 20.
3. Cortes JE, Baccarani M, Guilhot F, et al. First report of the TOPS study: a randomized phase III trial of 400 mg vs. 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints [abstract #402]. Haematologica 2008; 93.
4. Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg/day of imatinib as initial therapy. Blood 2008; 112:3965-3973. This study reports on the outcome of initial dose escalation of imatinib and aggressive dose optimization in chronic phase CML patients.
5. Cortes J, O'Brien S, Jabbour E, et al. Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract #29], Blood 2007; 110.
6. Cortes J, O'Brien S, Jones D, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract #30]. Blood 2007; 110.
7. National Comprehensive Cancer Network. NCCN: clinical practice guidelines in oncology. Chronic myelogenous leukemia. Version 3, 2008.
8. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108:1809-1820.
9. Marin D, Milojkovic D, Olavarria E, et al. European Leukemia Net criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112:4437-4444. This study analyzes the outcome of patients with CML on imatinib characterized as suboptimal and failure by Leukemia Net guidelines and illustrates that outcomes may be similar.
10. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 2007; 109:5143-5150. This paper reports on the only study randomizing imatinib failure patients to either higher dose imatinib or salvage with an alternative kinase inhibitor (here, dasatinib).
11. Kantarjian HM, Quintas-Cardama A, O'Brien S, et al. Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib [abstract #1036]. Blood 2007; 110.
12. Mauro MJ, Baccarani M, Cervantes F, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myetogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract #7009]. J Clin Oncol 2008; 26.
13. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540-3546. This study reports on the efficacy of nilotinib in the treatment of imatinib-resistant or intolerant chronic phase CML.
14. De Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008; 141:745-747. This study describes potential predisposing factors for the development of pleural effusions during dasatinib treatment.
15. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106:2128-2137.
16. Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26:3204-3212. This study reports on a 'dose optimization' study of dasatinib in chronic phase CML patients and the rationale behind reduction in the recommended dose to 100 mg daily.